Down 65% From Its 52-Week High, Is Viking Therapeutics Stock a Bargain Buy?

Viking Therapeutics (VKTX -0.07%) is a promising growth stock with a strong GLP-1 drug candidate in VK2735, which may eventually rake in significant revenue from the anti-obesity market. It has demonstrated encouraging results in clinical trials; however, it isn't approved just yet.While the optimism surrounding the drug made Viking's stock a hot buy early last year, things have drastically cooled over the past six months during which it has plummeted more than 50%. As a result, the stock is now down 65% fr ...